US 12,227,553 B2
De novo design of potent and selective interleukin mimetics
Daniel Adriano Silva Manzano, Seattle, WA (US); Shawn Yu, Seattle, WA (US); Umut Ulge, Seattle, WA (US); David Baker, Seattle, WA (US); Kenan Christopher Garcia, Seattle, WA (US); Jamie Spangler, Seattle, WA (US); and Carl Walkey, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON, Seattle, WA (US); and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Filed by UNIVERSITY OF WASHINGTON, Seattle, WA (US); and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Filed on Mar. 21, 2023, as Appl. No. 18/187,639.
Application 18/187,639 is a continuation of application No. 17/473,731, filed on Sep. 13, 2021, granted, now 11,655,278.
Application 17/473,731 is a continuation of application No. 16/905,669, filed on Jun. 18, 2020, granted, now 11,117,944.
Application 16/905,669 is a continuation of application No. 16/572,038, filed on Sep. 16, 2019, granted, now 10,703,791.
Application 16/572,038 is a continuation of application No. PCT/US2019/038703, filed on Jun. 24, 2019.
Claims priority of provisional application 62/768,733, filed on Nov. 16, 2018.
Claims priority of provisional application 62/689,769, filed on Jun. 25, 2018.
Prior Publication US 2024/0076342 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/55 (2006.01); A61K 38/00 (2006.01); A61K 47/60 (2017.01); A61K 47/62 (2017.01); C07K 14/54 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 47/60 (2017.08); A61K 47/62 (2017.08); C07K 14/5406 (2013.01); C07K 14/5437 (2013.01); C07K 14/5443 (2013.01); A61K 38/00 (2013.01); C07B 2200/13 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01)] 13 Claims
 
1. A recombinant host cell comprising an expression vector, wherein the expression vector comprises a nucleic acid operatively linked to a promoter, wherein the nucleic acid encodes a non-naturally occurring polypeptide wherein the polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 181, wherein the polypeptide binds to IL-2 receptor βYc heterodimer (IL-2RβYc).